Custom Search
ADVERTISEMENT
Today's Health Headlines
FRANKFURT (Reuters) - Germany's Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the U.S. market, hoping for blockbuster sales despite regulatory concerns about side effects having frustrated its ambitions almost seven years ago.

LONDON (Reuters) - An ingredient in cannabis called cannabidiol or CBD has shown promise in a clinical trial as a potential new treatment for psychosis, scientists said on Friday.

COPENHAGEN (Reuters) - Following a string of food safety scandals, Chinese tourists visiting Copenhagen have this year stocked up on Danish-made organic infant milk formula, prompting some supermarkets to limit the number of cans each customer can buy.

COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk came closer to winning European approval for diabetes drug Ozempic, its biggest growth prospect, when a European Medicines Agency (EMA) experts' panel issued a positive recommendation on Friday.

NEW DELHI (Reuters) - An Indian court on Friday quashed federal rules that mandated stringent graphic health warnings on tobacco products, lawyers involved in the case said, in a decision seen as a major victory for the tobacco industry and a setback for health advocates.

(Reuters) - The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical trials on a drug to treat patients with a rare bleeding disorder, the company said on Friday.

(Reuters) - Aclaris Therapeutics Inc's drug to treat a common kind of skin growth called seborrheic keratoses received approval from the U.S. Food and Drug Administration, the company said on Friday.

FRANKFURT (Reuters) - Siemens said it has agreed to buy Luxembourg-based Fast Track Diagnostics to boost its molecular-testing offering, one of the areas it is keen to expand as it prepares to float its healthcare unit, Healthineers.

BO RAI, Thailand (Reuters) - Once a smuggling stop for Cambodia's Khmer Rouge guerrillas, Thailand's border town of Bo Rai finds itself on the frontline of a new battle against drug-resistant strains of malaria that could frustrate global attempts to stamp out the disease.

LONDON (Reuters) - The European drugs agency said on Friday its new headquarters in Amsterdam may not be ready by the time it has to leave London due to Brexit because the building will not be completed.

ADVERTISEMENT
Make OUR Portal, YOUR Portal
Username: 
Password:
 Remember Remember me 
Not a Customer? Click here!
Browse RSS Feeds
click here when finished
Save Page Layout
Video
loading